Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLBT
stocks logo

CLBT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
125.92M
+15.48%
0.138
+37.84%
125.20M
+16.41%
0.110
+9.8%
131.33M
+15.94%
0.124
+3.58%
Estimates Revision
The market is revising Upward the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by 0.61% over the past three months. During the same period, the stock price has changed by 9.57%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.1%
In Past 3 Month
Stock Price
Go Up
up Image
+9.57%
In Past 3 Month
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.83 USD with a low forecast of 23.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.83 USD with a low forecast of 23.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.200
sliders
Low
23.00
Averages
24.83
High
28.00
Current: 18.200
sliders
Low
23.00
Averages
24.83
High
28.00
JPMorgan
Brian Essex
Overweight
maintain
$23 -> $24
2025-11-13
Reason
JPMorgan
Brian Essex
Price Target
$23 -> $24
2025-11-13
maintain
Overweight
Reason
JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $24 from $23 and keeps an Overweight rating on the shares. The company reported solid Q3 results with "multiple levers" to drive growth in 2026, the analyst tells investors in a research note.
BofA
Buy
maintain
$24 -> $25
2025-11-13
Reason
BofA
Price Target
$24 -> $25
2025-11-13
maintain
Buy
Reason
BofA raised the firm's price target on Cellebrite to $25 from $24 and keeps a Buy rating on the shares. The firm fine tunes its estimates to reflect positive underlying trends following the company's Q3 report.
Lake Street
Buy
maintain
$22 -> $23
2025-11-13
Reason
Lake Street
Price Target
$22 -> $23
2025-11-13
maintain
Buy
Reason
Lake Street raised the firm's price target on Cellebrite to $23 from $22 and keeps a Buy rating on the shares. The firm was "pleased to see Cellebrite get back on track" following what it calls out as "two consecutive quarters of disappointment." The firm, which raised its 2025 estimates, tells investors that the strength in U.S. state and local and LATAM have it "feeling more confident the business is back on the right track."
JPMorgan
Brian Essex
Overweight
maintain
$20 -> $23
2025-09-24
Reason
JPMorgan
Brian Essex
Price Target
$20 -> $23
2025-09-24
maintain
Overweight
Reason
JPMorgan analyst Brian Essex raised the firm's price target on Cellebrite to $23 from $20 and keeps an Overweight rating on the shares. The firm updated security software models post the earnings reports. The results reflect a stable to improving macro environment for security software, the analyst tells investors in a research note. The firm says companies exposed to large enterprise budgets and high priority spending categories are better positioned. It added Varonis Systems (VRNS) to JPMorgan Analyst Focus List and reiterated Cellebrite (CLBT) as a focus list pick.
Lake Street
Eric Martinuzzi
Buy
downgrade
$24 -> $22
2025-08-15
Reason
Lake Street
Eric Martinuzzi
Price Target
$24 -> $22
2025-08-15
downgrade
Buy
Reason
Lake Street analyst Eric Martinuzzi lowered the firm's price target on Cellebrite to $22 from $24 and keeps a Buy rating on the shares. Slower-moving Q1 deals in Europe came through in Q2, but the U.S. federal softness persisted in Q2 and is "not expected to break loose until October," the analyst tells investors in a post-earnings note. The federal issue will lower 2025 revenue more than originally expected, so the firm is trimming its estimates, the analyst added.
BofA
analyst
Buy
downgrade
$25 -> $24
2025-08-14
Reason
BofA
analyst
Price Target
$25 -> $24
2025-08-14
downgrade
Buy
Reason
BofA lowered the firm's price target on Cellebrite to $24 from $25 and keeps a Buy rating on the shares. Q2 results and second half guidance were below Street expectations on lasting DOGE efficiency impacts and budget pauses, but "the good news is that it is only a matter of timing," says the analyst, who believes the company should obtain FedRAMP High ATO status by the first half of 2026, further supporting cloud growth in Federal.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cellebrite DI Ltd (CLBT.O) is 34.58, compared to its 5-year average forward P/E of 46.49. For a more detailed relative valuation and DCF analysis to assess Cellebrite DI Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
46.49
Current PE
34.58
Overvalued PE
70.19
Undervalued PE
22.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
26.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
39.19
Undervalued EV/EBITDA
13.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.32
Current PS
0.00
Overvalued PS
7.81
Undervalued PS
2.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLBT News & Events

Events Timeline

(ET)
2025-12-02
08:10:00
Cellebrite Expands Capabilities with Corellium Acquisition
select
2025-11-13 (ET)
2025-11-13
12:01:51
Cellebrite's Stock Increases by 23.6%
select
2025-11-13
10:01:35
Cellebrite's Stock Soars by 24.4%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Newsfilter
Cellebrite Acquires Corellium for $170 Million, Enhancing Digital Investigation Capabilities
  • Acquisition Expansion: Cellebrite has acquired Corellium for $170 million, with $150 million paid in cash, significantly enhancing its technological leadership in the digital investigation space, thereby improving its competitive position in the market.
  • Technology Integration: Corellium's virtualization software enables investigators to work without physical device constraints, dramatically accelerating evidence acquisition and threat detection, which meets defense and intelligence customers' needs for secure mobile application development.
  • Customer Value Enhancement: By integrating Corellium's technology, Cellebrite can provide enterprise development and security operations teams with more efficient design and validation capabilities for next-generation mobile applications, thereby increasing customer satisfaction and market share.
  • Leadership Change: Corellium co-founder Chris Wade has joined Cellebrite as Chief Technology Officer, which is expected to drive customer-focused innovation and further enhance the company's technological strength and market influence.
[object Object]
Preview
2.0
11-18Benzinga
This Week's Fast-Growing Tech Stocks See Significant Increases in Growth Ratings

  • Taiwan Semiconductor Growth: Taiwan Semiconductor Inc. experienced a remarkable 291% increase in its growth score, reaching 85.46, while its stock trades at $282.01, showing bearish momentum despite strong fundamentals.

  • SkyWater Technology Performance: SkyWater Technology Inc. saw its growth score rise by 169% to 84.38, with its stock currently at $16.61, indicating neutral conditions and a solid overall Edge score of 80.28.

  • Cellebrite's Growth Surge: Cellebrite DI Inc. reported a 102% increase in its growth score to 98.07, trading at $18.17, with bullish momentum and a strong Edge score of 75.30.

  • Intellicheck's Notable Increase: Intellicheck Inc. achieved a 132% growth score increase to 78.48, with its stock at $6.19, showing mixed fundamentals but a noteworthy momentum score of 95.77.

[object Object]
Preview
4.0
11-14Benzinga
JP Morgan Keeps Overweight Rating on Cellebrite DI and Increases Price Target to $24

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cellebrite DI Ltd (CLBT) stock price today?

The current price of CLBT is 18.2 USD — it has increased 1.11 % in the last trading day.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s business?

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

arrow icon

What is the price predicton of CLBT Stock?

Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 24.83 USD with a low forecast of 23.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s revenue for the last quarter?

Cellebrite DI Ltd revenue for the last quarter amounts to 126.03M USD, increased 17.94 % YoY.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s earnings per share (EPS) for the last quarter?

Cellebrite DI Ltd. EPS for the last quarter amounts to 0.08 USD, decreased -108.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cellebrite DI Ltd (CLBT)'s fundamentals?

The market is revising Upward the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by 0.61% over the past three months. During the same period, the stock price has changed by 9.57%.
arrow icon

How many employees does Cellebrite DI Ltd (CLBT). have?

Cellebrite DI Ltd (CLBT) has 1167 emplpoyees as of December 05 2025.

arrow icon

What is Cellebrite DI Ltd (CLBT) market cap?

Today CLBT has the market capitalization of 4.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free